GB2401175A - Detection of SARS virus by PCR - Google Patents
Detection of SARS virus by PCR Download PDFInfo
- Publication number
- GB2401175A GB2401175A GB0310181A GB0310181A GB2401175A GB 2401175 A GB2401175 A GB 2401175A GB 0310181 A GB0310181 A GB 0310181A GB 0310181 A GB0310181 A GB 0310181A GB 2401175 A GB2401175 A GB 2401175A
- Authority
- GB
- United Kingdom
- Prior art keywords
- nucleic acid
- sars coronavirus
- dna
- seq
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000315672 SARS coronavirus Species 0.000 title claims description 89
- 238000001514 detection method Methods 0.000 title claims description 53
- 230000003321 amplification Effects 0.000 claims abstract description 52
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 50
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims abstract description 39
- 241000711573 Coronaviridae Species 0.000 claims abstract description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 87
- 102000039446 nucleic acids Human genes 0.000 claims description 80
- 108020004707 nucleic acids Proteins 0.000 claims description 80
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 68
- 239000000523 sample Substances 0.000 claims description 56
- 108020004414 DNA Proteins 0.000 claims description 50
- 239000002299 complementary DNA Substances 0.000 claims description 38
- 239000002773 nucleotide Substances 0.000 claims description 33
- 125000003729 nucleotide group Chemical group 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 238000003753 real-time PCR Methods 0.000 claims description 23
- 230000000295 complement effect Effects 0.000 claims description 22
- 102000053602 DNA Human genes 0.000 claims description 17
- 239000012472 biological sample Substances 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 11
- 230000003362 replicative effect Effects 0.000 claims description 11
- 238000002405 diagnostic procedure Methods 0.000 claims description 9
- 238000002955 isolation Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 230000007613 environmental effect Effects 0.000 claims description 7
- 230000004544 DNA amplification Effects 0.000 claims description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102100034343 Integrase Human genes 0.000 claims description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 241001048510 SARS coronavirus AS Species 0.000 claims 8
- 239000013615 primer Substances 0.000 abstract description 47
- 108090000623 proteins and genes Proteins 0.000 abstract description 28
- 239000003155 DNA primer Substances 0.000 abstract description 5
- 239000013610 patient sample Substances 0.000 abstract description 4
- 108020001019 DNA Primers Proteins 0.000 abstract 1
- 238000010240 RT-PCR analysis Methods 0.000 abstract 1
- 238000003752 polymerase chain reaction Methods 0.000 description 35
- 108020004635 Complementary DNA Proteins 0.000 description 25
- 238000010804 cDNA synthesis Methods 0.000 description 25
- 229920002477 rna polymer Polymers 0.000 description 18
- 230000008569 process Effects 0.000 description 15
- 239000000872 buffer Substances 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 10
- 108020000999 Viral RNA Proteins 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000319420 SARS coronavirus HKU-39849 Species 0.000 description 4
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 4
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000007857 nested PCR Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000003019 stabilising effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- -1 MgCI2 Proteins 0.000 description 1
- 101100026203 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) neg-1 gene Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0310181A GB2401175A (en) | 2003-05-02 | 2003-05-02 | Detection of SARS virus by PCR |
| TW093112238A TWI377255B (en) | 2003-05-02 | 2004-04-30 | Nucleic acid detection |
| EP04730463A EP1620556A4 (en) | 2003-05-02 | 2004-04-30 | NUCLEIC PROOF |
| KR1020117004874A KR20110027854A (ko) | 2003-05-02 | 2004-04-30 | 핵산 검출 방법 |
| TW101123035A TW201245452A (en) | 2003-05-02 | 2004-04-30 | Nucleic acid detection |
| KR1020127020392A KR20120094155A (ko) | 2003-05-02 | 2004-04-30 | 핵산 검출 방법 |
| CNA200480014935XA CN1798842A (zh) | 2003-05-02 | 2004-04-30 | 核酸检测 |
| EP12199212.7A EP2597162A1 (en) | 2003-05-02 | 2004-04-30 | Nucleic acid detection |
| PCT/CN2004/000434 WO2004097021A1 (en) | 2003-05-02 | 2004-04-30 | Nucleic acid detection |
| KR1020107016726A KR101097560B1 (ko) | 2003-05-02 | 2004-04-30 | 핵산 검출 방법 |
| TW100121077A TWI362419B (en) | 2003-05-02 | 2004-04-30 | Nucleic acid detection |
| US10/555,467 US20080090224A1 (en) | 2003-05-02 | 2004-04-30 | Nucleic acid detection |
| JP2006504214A JP4950656B2 (ja) | 2003-05-02 | 2004-04-30 | 核酸検出 |
| KR1020057020758A KR101158934B1 (ko) | 2003-05-02 | 2004-04-30 | 핵산 검출 방법 |
| JP2011235645A JP2012080884A (ja) | 2003-05-02 | 2011-10-27 | 核酸検出 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0310181A GB2401175A (en) | 2003-05-02 | 2003-05-02 | Detection of SARS virus by PCR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB2401175A true GB2401175A (en) | 2004-11-03 |
Family
ID=33155801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0310181A Withdrawn GB2401175A (en) | 2003-05-02 | 2003-05-02 | Detection of SARS virus by PCR |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20080090224A1 (https=) |
| EP (2) | EP2597162A1 (https=) |
| JP (2) | JP4950656B2 (https=) |
| KR (4) | KR101097560B1 (https=) |
| CN (1) | CN1798842A (https=) |
| GB (1) | GB2401175A (https=) |
| TW (3) | TWI362419B (https=) |
| WO (1) | WO2004097021A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111304369A (zh) * | 2020-02-06 | 2020-06-19 | 中山大学达安基因股份有限公司 | 新型冠状病毒双重检测试剂盒 |
| CN111455102A (zh) * | 2020-04-09 | 2020-07-28 | 上海符贝基因科技有限公司 | 用于新冠病毒SARS-CoV-2基因组靶向测序的捕获探针制备方法 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101603096A (zh) * | 2009-05-04 | 2009-12-16 | 北京海康基因芯片开发有限公司 | 一种检测传染病病原体的方法及试剂盒 |
| CN102424863B (zh) * | 2012-01-06 | 2013-06-12 | 海康生物科技（北京）有限公司 | 一种增强型荧光定量pcr方法 |
| US11130994B2 (en) * | 2019-12-13 | 2021-09-28 | Autonomous Medical Devices Inc. | Automated, cloud-based, point-of-care (POC) pathogen and antibody array detection system and method |
| US12416053B2 (en) * | 2020-02-04 | 2025-09-16 | Indian Institute Of Technology Delhi | Primer sets, biomarkers, kit and applications thereof |
| IT202000006754A1 (it) | 2020-03-31 | 2021-10-01 | Diasorin S P A | Saggi per la rivelazione di SARS-CoV-2 |
| US11149320B1 (en) | 2020-03-31 | 2021-10-19 | Diasorin S.P.A. | Assays for the detection of SARS-CoV-2 |
| AU2021202504A1 (en) * | 2020-04-29 | 2021-11-18 | Teleflex Medical Incorporated | System for identifying severe acute respiratory syndrome corona virus 2 (sars-cov-2) ribonucleic acid (rna) |
| CN111635960B (zh) * | 2020-05-06 | 2023-06-27 | 温州医科大学附属眼视光医院 | 用于稳态速效检测新型冠状病毒的保护序列、引物、探针、组合物、试剂盒及应用和方法 |
| WO2021247398A1 (en) * | 2020-05-30 | 2021-12-09 | Pangolin Llc | Systems and methods to detect pathogens |
| JPWO2022030629A1 (https=) * | 2020-08-07 | 2022-02-10 | ||
| US11361847B1 (en) | 2021-02-06 | 2022-06-14 | Timothy A. Hodge | System and method for rapidly reporting testing results |
| KR102625074B1 (ko) * | 2021-04-20 | 2024-01-16 | 재단법인 아산사회복지재단 | 마이크로입자 기반 핵산 검출용 키트 및 핵산 증폭산물 검출 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1493602A (en) * | 2000-10-05 | 2002-04-15 | Hong Kong Dna Chips Ltd | A kit for detecting non-pathogenic or pathogenic influenza a subtype h5 virus |
| US6617137B2 (en) * | 2001-10-15 | 2003-09-09 | Molecular Staging Inc. | Method of amplifying whole genomes without subjecting the genome to denaturing conditions |
| AU2002346660A1 (en) * | 2001-11-30 | 2003-06-17 | University Of Rochester | Multiplex real-time quantitative pcr |
| WO2004085455A1 (en) * | 2003-03-24 | 2004-10-07 | The University Of Hong Kong | A diagnostic assay for the human virus causing severe acute respiratory syndrome (sars) |
| CN102021147B (zh) * | 2003-03-24 | 2016-08-03 | 港大科桥有限公司 | 引起严重急性呼吸道综合征(sars)的新型人病毒及其应用 |
| ES2529736T3 (es) * | 2003-04-10 | 2015-02-25 | Novartis Vaccines And Diagnostics, Inc. | Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS |
| EP1616038A2 (en) * | 2003-04-21 | 2006-01-18 | Genome Institute of Singapore | Reagents and methods for detecting severe acute respiratory syndrome coronavirus |
| CN1442488A (zh) * | 2003-05-16 | 2003-09-17 | 上海晶泰生物技术有限公司 | 传染性非典型肺炎（sars）病毒复合荧光定量pcr检测 |
-
2003
- 2003-05-02 GB GB0310181A patent/GB2401175A/en not_active Withdrawn
-
2004
- 2004-04-30 EP EP12199212.7A patent/EP2597162A1/en not_active Withdrawn
- 2004-04-30 JP JP2006504214A patent/JP4950656B2/ja not_active Expired - Fee Related
- 2004-04-30 KR KR1020107016726A patent/KR101097560B1/ko not_active Expired - Fee Related
- 2004-04-30 TW TW100121077A patent/TWI362419B/zh not_active IP Right Cessation
- 2004-04-30 TW TW093112238A patent/TWI377255B/zh not_active IP Right Cessation
- 2004-04-30 KR KR1020057020758A patent/KR101158934B1/ko not_active Expired - Fee Related
- 2004-04-30 WO PCT/CN2004/000434 patent/WO2004097021A1/en not_active Ceased
- 2004-04-30 EP EP04730463A patent/EP1620556A4/en not_active Withdrawn
- 2004-04-30 TW TW101123035A patent/TW201245452A/zh unknown
- 2004-04-30 KR KR1020127020392A patent/KR20120094155A/ko not_active Ceased
- 2004-04-30 KR KR1020117004874A patent/KR20110027854A/ko not_active Abandoned
- 2004-04-30 US US10/555,467 patent/US20080090224A1/en not_active Abandoned
- 2004-04-30 CN CNA200480014935XA patent/CN1798842A/zh active Pending
-
2011
- 2011-10-27 JP JP2011235645A patent/JP2012080884A/ja not_active Withdrawn
Non-Patent Citations (2)
| Title |
|---|
| Acad. J. First Med. College PLA 23 (5) 2003. Yang J et.al. pages 424-427 * |
| N. Engl. J. Med. 348 2003. (epublished April 2003). Drosten C et.al. pages 1967-1976 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111304369A (zh) * | 2020-02-06 | 2020-06-19 | 中山大学达安基因股份有限公司 | 新型冠状病毒双重检测试剂盒 |
| CN111304369B (zh) * | 2020-02-06 | 2023-06-30 | 广州达安基因股份有限公司 | 新型冠状病毒双重检测试剂盒 |
| CN111455102A (zh) * | 2020-04-09 | 2020-07-28 | 上海符贝基因科技有限公司 | 用于新冠病毒SARS-CoV-2基因组靶向测序的捕获探针制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110027854A (ko) | 2011-03-16 |
| KR20050118738A (ko) | 2005-12-19 |
| CN1798842A (zh) | 2006-07-05 |
| WO2004097021A1 (en) | 2004-11-11 |
| JP4950656B2 (ja) | 2012-06-13 |
| KR101097560B1 (ko) | 2011-12-22 |
| TWI362419B (en) | 2012-04-21 |
| EP1620556A4 (en) | 2010-09-15 |
| TW201139687A (en) | 2011-11-16 |
| JP2012080884A (ja) | 2012-04-26 |
| TW201245452A (en) | 2012-11-16 |
| EP1620556A1 (en) | 2006-02-01 |
| TWI377255B (en) | 2012-11-21 |
| EP2597162A1 (en) | 2013-05-29 |
| US20080090224A1 (en) | 2008-04-17 |
| KR20100090730A (ko) | 2010-08-16 |
| TW200502400A (en) | 2005-01-16 |
| KR20120094155A (ko) | 2012-08-23 |
| JP2006524996A (ja) | 2006-11-09 |
| KR101158934B1 (ko) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111593145B (zh) | 一种CRISPR/Cas12一步核酸检测方法及新型冠状病毒检测试剂盒 | |
| Mota et al. | Recombinase polymerase amplification in the molecular diagnosis of microbiological targets and its applications | |
| JP2012080884A (ja) | 核酸検出 | |
| CN111394431B (zh) | 一种使用双重实时荧光等温扩增技术检测核酸的方法 | |
| CN111334614A (zh) | 一种采用RT-qPCR技术检测新型冠状病毒的方法 | |
| CN112322705A (zh) | 一种用于多重核酸检测的恒温扩增荧光rma方法 | |
| WO2023207909A1 (zh) | 基于crispr的核酸检测试剂盒及其应用 | |
| CN114214455B (zh) | 乙肝病毒DNA快速定量引物探针及其CRISPR/Cas12b检测系统 | |
| CN111500792A (zh) | 一种新型冠状病毒检测试剂盒 | |
| CN111521781A (zh) | 一种用于新冠肺炎病毒SARS-CoV-2核酸的检测试剂盒及其检测方法 | |
| CN102212615A (zh) | 基于耐高温RNase HII的单核苷酸多态性检测方法 | |
| Maaroufi et al. | Development of a multiple internal control for clinical diagnostic real-time amplification assays | |
| CN116083655B (zh) | 一种用于I-IV型登革病毒检测的DENV-crRNA及其试剂盒和应用 | |
| CN113512598B (zh) | 百日咳杆菌的实时荧光核酸恒温扩增检测试剂盒及其专用引物和探针 | |
| CN106868177B (zh) | 一种新型核酸荧光定量检测方法 | |
| RU2795016C1 (ru) | Олигонуклеотиды для определения мутации S:delVYY143-145 SARS-CoV-2 | |
| KR102695296B1 (ko) | CRISPR-Cas 기반의 노로바이러스 GII.4 특이적 검출이 가능한 신규 가이드 RNA 및 이의 활용 | |
| US20250215512A1 (en) | Methods of treating dimorphic fungal diseases | |
| CN113337638A (zh) | 一种新型冠状病毒（SARS-CoV-2）的检测方法和试剂盒 | |
| KR102695295B1 (ko) | CRISPR-Cas 기반의 노로바이러스 GII.3 특이적 검출이 가능한 신규 가이드 RNA 및 이의 활용 | |
| US20250122586A1 (en) | Compositions and methods for the detection of h3n2 influenza variants | |
| KR20250059620A (ko) | SARS-CoV-2 검출용 조성물 및 이를 이용한 SARS-CoV-2 검출방법 | |
| Chupin | Construction of Newcastle disease virus LaSota strain-based internal sample for rabies diagnosis with RT-PCR | |
| US20120107796A1 (en) | Methods and kits to detect new h1n1 "swine flu" variants | |
| CN121227907A (zh) | 一种基于Cas12a变构调节实现肺炎支原体便携式超敏检测试剂盒及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |